

Embargo: April 1, 2009 at 1:30 PM (Brussels Time)

**SOLVAY CONFIRMS IT IS PROCEEDING WITH AN ANALYSIS OF VARIOUS
OPTIONS FOR ITS PHARMACEUTICAL ACTIVITIES**

Solvay Group wishes to react to the rumours reported today in a press article.

Within the framework of its strategy, it is Solvay's policy to constantly review its activities with a view to validate the ability of these activities to contribute to the realization of the Group's objectives.

In particular, Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities.

Conducting this analysis involves various contacts and discussions with third parties.

At this stage, this does not involve any other decision in this respect.

SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 29,000 people in 50 countries. In 2008, its consolidated sales amounted to EUR 9.5 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at www.solvay.com.

For further information please contact:

ERIK DE LEYE

Corporate Press Officer

SOLVAY S.A.

Tel: 32 2 509 7230

erik.deleye@solvay.com

www.solvaypress.com

PATRICK VERELST

Investor Relations

SOLVAY S.A.

Tel. 32 2 509 7243

patrick.verelst@solvay.com

www.solvay-investors.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar